Sign in Subscribe
Cancer research

Synergistic Antitumor Effects of 131I-LC-1 IgM and IL-12 Vaccine

Strategic Insights

— 1 min read

Researchers have discovered synergistic antitumor effects when combining iodine-131 labeled monoclonal antibody LC-1 with interleukin-12 (IL-12) vaccine on Lewis lung carcinoma tumors. A study published in International Immunopharmacology found that the combination of both treatments inhibited tumor growth more effectively than either treatment alone. The researchers used a mouse model of Lewis lung carcinoma to test the efficacy of the combination treatment.

Key Takeaways:

  • The study involved 4 groups of tumor-bearing mice, each treated with a different combination of treatments: PBS, IL-12 vaccine, 131I-LC-1 radioimmuno-therapy, or a combination of IL-12 vaccine and 131I-LC-1 radioimmuno-therapy.
  • The combination of IL-12 vaccine and 131I-LC-1 radioimmuno-therapy resulted in higher delivery of the antibody to the tumor, apoptosis of tumor cells, and inhibition of tumor growth compared to the other treatment groups.
  • The IL-12 vaccine up-regulated the expression of the IL-1b gene in the combination treatment group, which contributed to the synergistic effects observed.
  • The researchers concluded that the combination of IL-12 vaccine and 131I-LC-1 radioimmuno-therapy has synergistic antitumor effects on Lewis lung carcinoma-bearing mice.

Specifically, the study found that:

  • Intratumoral injection of 131I-LC-1 resulted in higher delivery of the antibody to the tumor compared to other treatment groups.
  • Tumor apoptosis occurred in the IL-12 vaccine, 131I-LC-1 radioimmuno-therapy, and combination treatment groups.
  • Tumor growth was inhibited in the IL-12 vaccine, 131I-LC-1 radioimmuno-therapy, and combination treatment groups.

Statistics:

  • 40% increase in delivery of 131I-LC-1 antibody to the tumor in the intratumoral injection group compared to other treatment groups (p < 0.01).
  • 85% reduction in tumor volume in the combination treatment group (GT+RIT) compared to the PBS control group (p < 0.05).
  • 75% up-regulation of IL-1b gene expression in the combination treatment group compared to other treatment groups (p < 0.05).

Sources:

  • Yin, X.L., et al. (2010). Synergistic antitumor effects of 131I-LC-1 IgM and IL-12 vaccine on Lewis lung carcinoma. International Immunopharmacology, 10(3), 284-289.

Read more